AmgenFRA:AMG +2.20%87 Market Cap is €170,223 Mil as of Jun. 28, 2026. GuruFocus rates FRA:AMG with a GF Score™ of 87/100 and a GF Value™ of €308.97 (Fairly Valued). The stock has 7 warning signs investors should review. Among 1,020 Drug Manufacturers companies, Amgen ranks better than 99.12% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Amgen's share price for the quarter that ended in Mar. 2026 was €303.85. Amgen's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 540 Mil. Therefore, Amgen's market cap for the quarter that ended in Mar. 2026 was €163,988 Mil.
Amgen's quarterly market cap
increased
from Sep. 2025 (€129,590 Mil) to Dec. 2025 (€150,541 Mil) and
increased
from Dec. 2025 (€150,541 Mil) to Mar. 2026 (€163,988 Mil).
Amgen's annual market cap
declined
from Dec. 2023 (€138,990 Mil) to Dec. 2024 (€134,169 Mil) but then
increased
from Dec. 2024 (€134,169 Mil) to Dec. 2025 (€150,541 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Amgen's Enterprise Value for Today is €210,082 Mil.
Amgen (FRA:AMG) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Amgen Market Cap Related Terms
Amgen Market Cap Historical Data
* Premium members only.
The historical data trend for Amgen's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Amgen's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amgen's Market Cap distribution charts can be found below:
* The bar in red indicates where Amgen's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Amgen's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen (FRA:AMG) has a Market Cap of €170,223 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Amgen and its competitors. According to the industry distribution chart, Amgen ranks #9 out of 1020 companies in the Drug Manufacturers industry, placing it in the top 0.90000000000001%.
Is Amgen's Market Cap too high?
Amgen's current Market Cap is €170,223 Mil. Based on the distribution chart, Amgen ranks #9 out of 1020 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Amgen has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Market Cap compare to GILD and PFE?
According to the Drug Manufacturers industry distribution chart, Amgen ranks #9 out of 1020 companies for Market Cap. This places Amgen in the top 1% of its industry — outperforming the majority of peers. The industry median Market Cap is 204.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 204.29, based on 1,020 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Amgen and its competitors. For the Drug Manufacturers industry, the median Market Cap is 204.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amgen's current Market Cap is €170,223 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (FRA:AMG) is currently considered Fairly Valued. The stock's GF Value™ is €308.97, compared to a current price of €313.15 — trading 1.4% above its estimated fair value. The current Market Cap is €170,223 Mil. Amgen's overall GF Score™ is 87/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Amgen (FRA:AMG), the current Market Cap is €170,223 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amgen (FRA:AMG) Overvalued in 2026?
Based on GuruFocus' analysis, Amgen stock appears to be overvalued.
The current stock price of €313.15 is trading 1.4% above its estimated GF Value™ of €308.97.
GuruFocus considers Amgen to be Fairly Valued.
Key valuation signals for FRA:AMG:
Market Cap: €170,223 Mil
GF Value™: €308.97 vs. price of €313.15 (1.4% above fair value)
No single metric tells the full story. See the FRA:AMG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
87GF Score
Get the complete analysis for FRA:AMG
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AMG has been successfully added to your 
